Moderna to Deliver 20 Million Doses of COVID-19 Vaccine to Argentina
Moderna announces supply agreement with the Argentina government for 20 million doses of Moderna’s COVID-19 vaccine.
Moderna. announced a supply agreement in a July 12, 2021 press release with the government of Argentina for 20 million doses of Moderna’s COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized. Delivery will begin the first quarter of 2022.
“We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates,” said Stéphane Bancel, Chief Executive Officer of Moderna, in a press release. “We are committed to making our vaccine available around the world as we seek to address the pandemic with our COVID-19 vaccine.”
The Moderna COVID-19 vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the spike protein. Moderna has received emergency authorization for the vaccine for adults from health agencies in more than 50 countries and an Emergency Use Listing from WHO.
Source: Moderna
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
